Crinetics Pharmaceuticals (CRNX) Q1 2025 earnings summary

Executive summary

• Preparing for the first anticipated commercial launch of paltusotine in 2025, with foundational infrastructure and field force in place by summer; NDA for acromegaly on track with FDA, PDUFA date set for September 25, 2025, and EMA review validated with Orphan Drug Designation granted.

• Deep pipeline with two late-stage programs (paltusotine and atumelnant) in multiple indications, plus several preclinical candidates; atumelnant advancing in phase III for CAH with novel endpoints.

• Robust financial position with $1.3B in cash, cash equivalents, and investments as of March 31, 2025, expected to fund operations into 2029.

• Corporate focus on endocrinology, patient support, and scientific innovation, with global expansion plans underway, starting with Germany and Brazil.

• Launch of CrinetiCARE patient support platform and disease education website for paltusotine ahead of product approval.

Financial highlights

• Q1 2025 revenue was $0.4M, down from $0.6M in Q1 2024, primarily from licensing; net loss widened to $96.8M from $66.9M year-over-year.

• R&D expenses rose to $76.2M from $53.3M year-over-year, driven by increased personnel, clinical activity, and portfolio expansion.

• SG&A expenses increased to $35.5M from $20.8M year-over-year, reflecting commercial launch preparations and higher headcount.

• Cash used in operations for Q1 2025 was $88.5M, up from $52.9M in Q1 2024.

• Cash, cash equivalents, and investments totaled $1.3B as of March 31, 2025.

Outlook and guidance

• Cash runway expected to last into 2029 based on current projections and anticipated cash use of $340M–$380M in 2025.

• Anticipates paltusotine launch in September 2025, with measured early uptake and progressive coverage; EMA decision expected in H1 2026.

• Phase 3 trials for paltusotine in carcinoid syndrome and atumelnant in CAH (adults and pediatrics) to begin in H2 2025.

• Expects R&D and SG&A expenses to increase sequentially through 2025; continued net losses and potential need for additional capital for long-term plans.

• Potential $250M milestone if Lilly exercises option to acquire Radionetics; strategic partnerships for development and commercialization.